deltatrials
Completed NA NCT00824707

Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer

A Randomized, Controlled Study to Evaluate the Efficacy and Significant of the Anti-virus Therapy for the Unresectable Hepatitis B Virus-related Primary Liver Cancer

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Primary Liver Cancer
Interventions Entecavir conventional therapy
Updated 5 times since 2017 Last updated: Mar 30, 2016 Started: Dec 31, 2008 Primary completion: Nov 30, 2010 Completion: Dec 31, 2010

A NA clinical study on Primary Liver Cancer, this trial is completed. The trial is conducted by Eastern Hepatobiliary Surgery Hospital and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Hepatobiliary Surgery Hospital
Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shanghai, China